More than a third of a modern woman’s life is spent in conditions of sex hormones deficiency. Hormonal changes that occur in menopause are accompanied by pronounced clinical manifestations: neuropsychic, vegetative-vascular, and metabolic disorders. Vasomotor symptoms, depression, urogenital disorders significantly worsen the quality of life of patients. However, the greatest danger to life is posed by late climacteric disorders: dyslipidemia and obesity, atherosclerosis, arterial hypertension, coronary artery disease (CAD), and osteoporosis. Gynecologists, therapists, general practitioners should contribute to the early detection of signs of climacteric disorders in patients, as well as prevent the consequences of estrogen deficiency in the future. Menopausal hormone therapy (MHT) during the menopausal transition and early menopause («window of therapeutic opportunities») allows women to maintain health during this difficult period of her life. The timely use of MHT effectively reduces not only the vasomotor and urogenital manifestations of climacteric syndrome, but also the risk of atherosclerosis, CAD, osteoporosis and significantly increases the quality of life of a woman as a whole.

Keywords: menopausal transition, menopausal hormone therapy, osteoporosis, metabolic syndrome, arterial hypertension